Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAetna Facial Nerve Paralysis Coverage & Prior Auth…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0745

    Facial Nerve Paralysis

    Customize your policy alerts

    Sign up for Aetna Policy 0745 alerts

    Get alerted when Policy 0745 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for diagnostic tests and surgical and non-surgical treatments for facial nerve paralysis (including Bell's palsy), specifying medically necessary services, and listing procedures considered experimental/investigational. Affects providers submitting claims to Aetna for members with facial nerve paralysis.

    Policy Summary
    PayerAetna
    PolicyFacial Nerve Paralysis
    Policy CodePolicy 0745
    Change TypeNo material change
    Effective DateFeb 8, 2008
    Last ReviewOct 30, 2025
    Next Review DateAug 27, 2026
    Key ActionObtain prior authorization when surgical reconstructive procedures or specified CPT/HCPCS codes are used and document chronicity, electrophysiologic testing, and prior conservative management.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >12 monthsRequired paralysis duration
    95933Blink reflex CPT
    67912Gold weight CPT
    G51.0Bell's palsy ICD-10
    Multiple proceduresExperimental procedures
    350ITST meta-analysis N

    Coverage Criteria for Facial Nerve Paralysis (Bell's Palsy)

    Facial surgery for chronic facial paralysis (medically necessary)

    Covered when ALL of the following are met:

    Surgical coverage criteria: 1) Facial paralysis has persisted for more than 12 months; and 2) Facial paralysis has resulted in impaired functional deficit in mastication, speech, or vision; and 3) There is no reasonable likelihood of spontaneous return of function as determined by electromyography or electroneuronography.

    Electrophysiologic testing required to document low likelihood of recovery.

    Blink reflex testing and gold weight eyelid implants (medically necessary)

    Covered items

    Diagnostic and eyelid implant coverage: 1) Blink reflex testing for the diagnosis of Bell's palsy; and 2) Gold weight eyelid implants for the treatment of Bell's palsy.

    Listed as medically necessary when indicated.

    Policy Summary
    PayerAetna
    PolicyFacial Nerve Paralysis
    Policy CodePolicy 0745
    Change TypeNo material change
    Effective DateFeb 8, 2008
    Last ReviewOct 30, 2025
    Next Review DateAug 27, 2026
    Key ActionObtain prior authorization when surgical reconstructive procedures or specified CPT/HCPCS codes are used and document chronicity, electrophysiologic testing, and prior conservative management.
    SourceLink
    On This Page
    Coverage Criteria for Facial Nerve Paralysis (Bell's Palsy)Coding and Key ThresholdsProvider Actions, Prior Authorization, and DocumentationBackground and Evidence SummaryDefinitions and Additional ResourcesRevision History

    Procedures considered experimental, investigational, or unproven (not covered)

    The following procedures/diagnostics are considered experimental/investigational/unproven for Bell's palsy:

    Experimental/Unproven list: Combined electrophysiological tests for predicting outcome; genetic analysis of facial muscle specimens; blood thiol/disulphide measurements; neuromuscular ultrasound; and numerous treatments including acupuncture, antiviral therapy, botulinum toxin, electrical stimulation, excision of depressor anguli oris, facial nerve decompression, facial retraining therapy, free functional platysma transfer, hyperbaric oxygen therapy, infrared therapy, intra-tympanic steroid injection, kinesio taping, laser acupuncture, Lyftogt perineural injection therapy, nerve growth factor, neural therapy, peripheral blood mononuclear cells/PRP transplantation, photobiomodulation, proprioceptive neuromuscular facilitation, surface EMG for evaluation/prognostication, telerehabilitation, transcranial magnetic stimulation, and Vitamin B-12.

    Effectiveness not established per policy.

    Treatment coverage logic

    Covered treatments with evidence-supported conditions

    Corticosteroid therapy for new-onset Bell's palsy: Offer corticosteroids started within early onset (e.g., within 72 hours) to increase probability of complete facial nerve recovery; evidence: randomized trials (Sullivan et al) and guideline reviews showing significant benefit at 3 and 9 months.start within 72 hours when possible

    Level A evidence per AAN review

    Antiviral therapy: Antivirals alone have not shown consistent benefit; antivirals may be offered in addition to steroids with counseling that benefit is unproven or modest; some meta-analyses suggest possible added benefit when combined with steroids but larger trials are mixed.if used, initiate early

    Mixed evidence; counsel patients on limited benefit

    Physical therapies (facial exercises, retraining, EMG biofeedback): Tailored facial exercises and neuromuscular retraining may benefit selected patients, particularly those with persistent deficits or synkinesis; evidence quality is low and methods heterogeneous; recommend trial before irreversible surgery when feasible.consider when persistent deficits or synkinesis present

    Evidence limited; use as first-line conservative management

    Surgical reconstruction and reanimation: Surgical nerve grafting, temporalis/masseter transfers, cross-facial nerve grafting, and free functional muscle transfer are options for long-standing paralysis or when no recovery by approximately 12 months; randomized evidence is very low quality—surgery should be individualized with thorough documentation and appropriate staging.consider if no return at ~12 months or earlier for defined indications (e.g., tumor resection with intraoperative repair)

    Requires multidisciplinary planning and prior authorization when applicable

    Surgical reanimation: approaches and decision factors

    Surgical reanimation approaches and relevant clinical considerations described in these sections:

    Reanimation options overview: Includes nerve continuity reconstruction (direct suture, grafts, transpositions), regional muscle transfer (temporalis), and microvascular free muscle transfer (commonly gracilis) often combined with cross-face nerve grafting.

    Choice depends on timing, etiology, and patient factors

    Choice considerations: Choice guided by duration since onset, patient age, etiology, presence of soft tissue deficits, and patient preference; staged CFNG with FFMT favored to restore spontaneous smile, while masseteric/motor nerve transfers may be chosen for single-stage reconstruction or limited life expectancy.

    Discuss goals (spontaneous mimetic function vs voluntary movement) in planning

    Adjunctive therapies: evidence summaries

    Adjunctive and non-surgical treatments with summarized evidence:

    Acupuncture: Systematic reviews/meta-analyses report association with higher effective response rates but included trials are heterogeneous and at high risk of bias; evidence insufficient to firmly support safety/effectiveness.

    Interpret cautiously due to study limitations

    Antivirals with corticosteroids: Cochrane and meta-analytic data indicate antivirals added to corticosteroids do not consistently improve recovery over steroids alone; corticosteroids alone reduce risk of unsatisfactory recovery.

    Antivirals may be considered with counseling about limited benefit

    Botulinum toxin: Limited randomized and observational data suggest BTX can improve facial symmetry and quality of life in chronic palsy and synkinesis; further RCTs are needed to define optimal use.

    May be used as targeted chemo-denervation for synkinesis

    Electrical stimulation: Small trials show mixed results and authoritative reviews recommend against routine use in acute Bell's palsy due to lack of controlled-trial evidence of benefit.

    Not recommended as standard acute therapy

    Intra-tympanic steroid therapy (ITST): Meta-analysis of small RCTs and cohorts (n≈350) suggests adding daily ITST to systemic corticosteroids may reduce non-recovery in Bell's palsy/Ramsay Hunt syndrome, but methods vary and further RCTs are needed.

    Considered investigational/adjunctive pending stronger evidence

    Candidates for facial nerve decompression

    Covered when ALL of the following are met

    Decompression candidate criteria: Patient has complete facial paralysis (e.g., House-Brackmann V–VI) AND electrophysiologic evidence of greater than 90% degeneration on electroneurography (ENoG) AND absent voluntary EMG within approximately 14 days of onset (when available).

    Middle cranial fossa decompression outcomes are better when performed ≤14 days; some retrospective data suggest benefit up to 90 days if earlier surgery is not possible.

    Intra-tympanic steroid therapy (ITST) for Bell's palsy/Ramsay Hunt

    Evidence and usage considerations

    ITST findings: Combination of systemic corticosteroid plus intra-tympanic corticosteroid may reduce non-recovery versus systemic corticosteroid alone; daily ITST regimens showed stronger reduction in non-recovery than non-daily regimens in pooled analyses of small trials/cohorts.

    Meta-analysis pooled 3 RCTs and 2 cohorts (n≈350); methods and timing varied across studies; further well-designed RCTs needed.

    Surgical management of post-paralytic synkinesis

    Surgical option and expected outcomes

    Combined myectomy/neurectomy + functioning free muscle transfer: For selected patients with type II/III post-paralytic synkinesis, combined removal of synkinetic muscles and selective neurectomy followed by functioning free muscle transplantation (e.g., gracilis FFMT) can improve smile quality and reduce synkinesis; many patients did not require Botox postoperatively but revision surgery rates are substantial.

    Reported outcomes: 96% avoided postoperative Botox; revision rate reported ~53%; evidence level IV; counsel patients on revision risk.

    Rehabilitative and adjunctive therapies (informational stance)

    Evidence summaries for non-surgical interventions

    Facial retraining and PNF: Facial retraining and proprioceptive neuromuscular facilitation may improve motor function and reduce synkinesis in some studies, but the overall quality of evidence is low to very low and protocols are heterogeneous.

    Recommend cautious interpretation; use as part of conservative management before irreversible surgery.

    Experimental/alternative therapies: Therapies including nerve growth factor, neural therapy, PBMC/PRP transplantation, laser acupuncture/photobiomodulation, acupuncture with kinesio taping and other adjuncts have preliminary or case-level evidence and require validation in well-designed trials.

    Available data are limited to small RCTs, pilot studies, and case reports.

    Selective myectomy/neurectomy for synkinesis — situational criteria

    Surgical selective myectomy or neurectomy may be considered when ALL of the following are met:

    criteria_set: 1) Clinically significant synkinesis causing functional impairment (for example, asymmetric smile or eyelid narrowing); 2) Failure or inadequate response to first-line treatments such as botulinum toxin (chemo-denervation) and neuromuscular retraining; 3) Individualized decision-making with informed discussion of potential complications, limited long-term evidence, and likelihood of revision surgery; 4) Objective pre- and post-operative assessments documented (e.g., eFACE, FaCE, photographic measures).

    Considered third-line; ensure documentation of prior conservative therapies and informed consent.

    Depressor anguli oris (DAO) excision — situational criteria

    DAO excision may be considered when ALL of the following are met:

    criteria_set: 1) Non-flaccid facial palsy with hypertonicity/synkinesis producing smile asymmetry and restricted oral commissure excursion; 2) Pre-operative DAO muscle block used to predict response (optional but informative); 3) Objective baseline and follow-up measurements (for example, Emotrics, clinician-graded scales, PROMs) are documented; 4) Patient counseled on expected modest improvements and risk profile.

    Cohort evidence shows modest improvements in commissure excursion and smile metrics; document outcome measures.

    Free functional platysma or other muscle transfers for eye/smile reanimation — situational criteria

    Free or pedicled muscle transfer for dynamic eye closure or smile restoration may be considered when ALL of the following are met:

    criteria_set: 1) Longstanding denervation (commonly greater than 18–24 months) with loss of spontaneous blink or orbicularis oculi function; 2) Objective impairment documented (for example, absence of blink reflex, palpebral fissure measurements, eFACE scores); 3) Conservative, less invasive options are not suitable or have failed; 4) Patient is a surgical candidate for microsurgical transfer with documented counseling on expected outcomes and comparative efficacy of pedicled versus free transfers.

    Pedicled temporalis is often first-line for eye reanimation; free transfers may restore spontaneous blink in some patients; document counseling and follow-up.

    Use of electrophysiological testing (ENoG, needle EMG, CMAP, NET, blink reflex, integrated EMG) — diagnostic/prognostic criteria

    Electrophysiologic testing may be used when ALL of the following apply:

    criteria_set: 1) Acute peripheral facial nerve palsy where prognostic information will influence management decisions; 2) Tests are performed within recommended time windows for each modality (for example, ENoG within early weeks; integrated EMG after Day 8 to 3 weeks in pediatric data); 3) Results are interpreted in combination with clinical grading (for example, House-Brackmann) to guide prognosis and counseling; 4) Standardized protocols are used where available and limitations are acknowledged in documentation.

    Combined use of multiple electrophysiologic tests can improve predictive accuracy (decision-tree model reported ~86% accuracy).

    Surface EMG (sEMG)

    sEMG may be considered as an objective assessment tool when ALL of the following are met:

    criteria_set: 1) sEMG is used as an adjunctive, noninvasive assessment of facial muscle symmetry/function; 2) Performed with standardized electrode placement and analysis methods; 3) Results are integrated with the clinical evaluation due to heterogeneity in current evidence; 4) Intended for serial objective monitoring or research/clinical assessment rather than as the sole basis for major surgical decisions.

    Evidence is limited and heterogeneous; methodological guidelines are encouraged.

    Lyftogt perineural injection therapy (LPIT)

    LPIT is considered investigational/experimental when ANY of the following apply:

    criteria_set: 1) Use of dextrose-based perineural injection therapy (Lyftogt LPIT) for chronic (>1 year) Bell's palsy is supported only by single-case reports; 2) LPIT lacks robust clinical evidence from controlled trials and therefore should be considered experimental or unproven pending validation in well-designed studies.

    Single-case report only; insufficient evidence for effectiveness.

    Telerehabilitation

    Telerehabilitation may be used when ALL of the following are met:

    criteria_set: 1) Rehabilitation services are clinically appropriate for the patient's condition; 2) Patient has access to required technology and remote delivery is feasible; 3) Safety considerations are addressed (risk mitigation for falls, aspiration); 4) Documentation of sessions and adverse events is maintained.

    Scoping review found related adverse events to be rare (~0.3% per session) and mostly mild; detailed AE reporting recommended.

    The policy lists specific CPT and HCPCS codes that are covered only when selection criteria are met (for example, 95933 for blink reflex testing and 67912 for gold weight eyelid implant) and identifies a set of procedure and supply codes that are not covered for the indications addressed in this document. Examples of codes called out as not covered for listed indications include the PRP injection code 0232T and multiple HCPCS device/supply codes for topical hyperbaric oxygen, TENS/NMES devices and supplies (e.g., A4575, A4595, E0720, E0730), botulinum toxin J-codes (e.g., J0585, J0587), and hyperbaric oxygen session code G0277. Providers should confirm coverage by matching the submitted code to the policy's listed covered and not-covered code groups and follow prior-authorization requirements where applicable.

    The document states that several adjunctive therapies lack sufficient high-quality evidence to be recommended for Bell's palsy. Specifically, hyperbaric oxygen therapy (HBOT), acupuncture, electrostimulation (electrotherapy), and chiropractic/osteopathic manipulation are described as having unestablished effectiveness and are listed among interventions without proven benefit. Systematic reviews and Cochrane-style evaluations cited in the policy emphasize heterogeneity, high risk of bias, and inadequate trial quality for these modalities, and the policy notes that further well-designed RCTs are needed before these therapies can be considered supported.

    The policy explains a limitation of techniques that rely on motor nerves or muscles outside the facial-nerve territory: procedures using non-facial donor motor nerves (for example, temporalis transposition, hypoglossal or spinal accessory neurotization) generally do not restore a truly spontaneous smile. Such approaches may be acceptable alternatives when facial-nerve neurotization is not feasible, but expectations for spontaneous mimetic function should be tempered when motor donors other than the facial nerve are employed.

    Delayed trans-mastoid decompression (TMD) was not associated with improved facial outcomes compared with medical management in the cited meta-analysis. The policy highlights that middle cranial fossa decompression (MFD) performed ≤14 days after symptom onset showed better outcomes than MFD performed after 14 days, but TMD — typically performed after 15 days in the reviewed studies — did not demonstrate benefit over non-surgical care, indicating limited support for TMD when performed late.

    Lyftogt perineural injection therapy (LPIT) for facial nerve palsy is supported in the document only by a single-case report. The policy therefore characterizes LPIT as unproven/experimental for chronic Bell's palsy and states that the promising single-case findings require validation in well-designed studies before LPIT can be considered an evidence-based therapy.

    The scoping reviews of telerehabilitation cited in the policy note several methodological limitations: heterogeneous nomenclature and inclusion criteria across digital-health studies, the potential for missed studies due to variable search terms, and the absence of critical appraisal in some reviews. These limitations restrict the certainty of conclusions about effectiveness and safety and the reviews recommend standardized, detailed reporting of interventions and adverse events (e.g., using TIDieR guidelines) for future work.

    Aetna provides links to external websites for convenience and explicitly states that it is not responsible for the content, accuracy, or privacy practices of those linked non-Aetna sites. Users are notified they are leaving the Aetna website and that Aetna disclaims liability for external site material.

    The policy and cited literature advise against routine use of electrotherapy/electrical stimulation and hyperbaric oxygen therapy for acute Bell's palsy. Historic reviews and systematic evaluations found no consistent evidence of benefit for electrical stimulation in acute cases and recommended against its routine use in the absence of controlled-trial evidence; similarly, HTA and review articles have concluded that HBOT is not supported for Bell's palsy.

    Randomized and quasi-randomized trials of surgical intervention for Bell's palsy provide very low-quality evidence and do not demonstrate clear benefit over medical management. The Cochrane-style reviews and updates cited in the policy conclude that evidence is insufficient to support routine early surgical intervention for Bell's palsy and that spontaneous recovery in most patients limits the feasibility and interpretation of further trials.

    The document reports that electrical stimulation applied during the acute phase of Bell's palsy lacks controlled-trial evidence of benefit. Case series and small studies offer mixed results and guideline reviews (including UpToDate summaries) recommend against electrical nerve stimulation in acute Bell's palsy until controlled, safety-focused trials demonstrate clear benefit.

    Cochrane and systematic-review updates concluded that evidence for early surgical intervention in Bell's palsy is of very low certainty. Current randomized/quasi-randomized trials are insufficient to determine whether early surgery is beneficial or harmful, and because most patients experience spontaneous or medically supported recovery, routine early surgical decompression remains unsupported.

    Selective myectomy or neurectomy for post-paralytic synkinesis is presented as a third-line, situational option. The policy emphasizes that routine use of these surgical procedures without prior trials of first- and second-line therapies (such as botulinum toxin chemo-denervation and neuromuscular retraining) is not supported; decisions for surgery should be individualized, follow documented conservative management attempts, and include counseling about limited long-term evidence and potential for revision.

    Within the cited excerpts there is no single explicit list labeled as 'not medically necessary.' Instead, the policy describes interventions that are considered experimental, unproven, or not advised for routine use (for example, electrotherapy and HBOT for acute Bell's palsy) and indicates that surgical procedures without clear indications or without demonstrated failure of conservative therapy may not be supported by the evidence.

    Coding and Key Thresholds

    Covered CPT/HCPCS Codes (selection criteria apply)mixedCovered
    15756Free muscle or myocutaneous flap with microvascular anastomosis.
    15758Free fascial flap with microvascular anastomosis.
    15840-15845Graft for facial nerve paralysis.
    20920-20922Fascia lata graft.
    61590Infratemporal pre-auricular approach to middle cranial fossa (parapharyngeal space, infratemporal and midline skull base, nasopharynx), with or without disarticulation of the mandible, including parotidectomy, craniotomy, decompression and/or mobilization of the facial nerve and/or petrous carotid artery.
    64716Neuroplasty and/or transposition; cranial nerve (specify).
    64742Transection or avulsion of; facial nerve, differential or complete.
    64864-64865Suture of facial nerve.
    64866-64868Anastomosis; facial-spinal, facial-hypoglossal or facial-phrenic.
    64885-64886Nerve graft (includes obtaining graft), head or neck.
    1–10 of 33
    1/4
    Not covered / Experimental, investigational, or unproven codesmixedNot Covered
    0232TInjection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
    0232T(listed among CPT codes not covered for indications in the CPB).
    76536Ultrasound, soft tissues of head and neck (eg, parotid) [neuromuscular ultrasound] (listed among items considered experimental/unproven).
    97810-97814Acupuncture codes (with/without electrical stimulation) (listed among items not covered/experimental).
    99183Physician attendance and supervision of hyperbaric oxygen therapy, per session (listed among HCPCS not covered for indications in the CPB).
    A4575,A4595,A4639,E0221,E0446,E0720,E0730,E0745,G0277,J0585,J0587,J3420,J3425,P9020,S2150Various HCPCS/Drug/Supply codes listed as not covered for indications in the CPB (e.g., topical hyperbaric oxygen, TENS devices, botulinum toxins, vitamin B-12 injections, PRP, stem cell-related codes).
    ICD-10 Diagnosis CodesICD-10
    G51.0Bell's palsy [facial palsy].
    Duration of paralysis before facial surgery — key threshold (> 12 months)
    Required duration before facial surgery> 12 months
    Functional deficit requirementImpaired mastication, speech, or vision must be present
    Electrophysiologic confirmationNo reasonable likelihood of spontaneous return as determined by EMG or ENoG
    Disulphide cutoff — numeric value
    Disulphide cutoff (study)18.95
    ContextCut-off derived from thiol/disulphide homeostasis study comparing Bell's palsy patients to controls
    Evidence notePreliminary finding requiring validation in well-designed studies
    ENoG degeneration threshold — > 90% denervation indicator for decompression consideration
    ENoG degeneration threshold for decompression consideration> 90% degeneration on ENoG
    Associated clinical stateComplete facial paralysis (e.g., HB V–VI) and absent voluntary EMG within ~14 days
    Surgical implicationMay indicate candidate for facial nerve decompression (middle cranial fossa approach) when other criteria met
    Timing thresholds for decompression — MFD ≤14 days vs >14 days; decompression may benefit if within 90 days when earlier surgery not possible
    MFD timing benefitMiddle cranial fossa decompression (MFD) performed ≤14 days yields better outcomes than >14 days
    TMD evidenceTrans-mastoid decompression (TMD) performed after 15 days did not show improved outcomes vs medical management
    Delayed decompression windowRetrospective data suggest possible benefit if decompression performed within 90 days when earlier surgery was not possible
    ENoG degeneration index threshold — 71.72% (orbicularis oculi)
    ENoG degeneration index threshold (orbicularis oculi)71.72%
    Role in prediction modelENoG DI <71.72% with lower initial HB grade associated with higher probability of complete recovery
    Source studyDecision-tree analysis integrating multiple electrophysiologic tests (Heo et al)
    NET difference threshold — 4.50 mA
    NET difference threshold4.50 mA
    InterpretationNET difference ≥4.50 mA in decision-tree predicted incomplete recovery in Heo et al study
    Use caseCombined with ENoG DI and CMAP latency to improve prognostic accuracy
    CMAP latency threshold — 3.80 ms (frontalis)
    CMAP latency threshold (frontalis)3.80 ms
    Predictive roleFrontalis CMAP latency >3.80 ms associated with incomplete recovery in decision-tree model
    Combined assessmentUsed alongside ENoG DI and NET difference to stratify prognosis
    Integrated EMG cutoff (pediatric study) — 25% (orbicularis oculi and oris)
    Integrated EMG cutoff (pediatric study)25% (orbicularis oculi and orbicularis oris)
    Prognostic implicationIntegrated EMG ≤25% at ~Week 2 indicates higher likelihood of incomplete recovery in children
    Combination ruleWhen integrated EMG ≤25% and ENoG <10%, pediatric study reported high sensitivity/specificity for predicting incomplete recovery
    ENoG cutoff (pediatric study) — 10%
    ENoG cutoff (pediatric study)10%
    Combined prognostic useENoG <10% plus integrated EMG ≤25% predicted incomplete recovery with high sensitivity in pediatric cohort
    Study contextPediatric cohort, tests performed after Day 8 and within 3 weeks of onset

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required when selection criteria are met

    Obtain prior authorization for the listed CPT/HCPCS codes when the policy selection criteria are met; authorization is required when submitting claims for covered facial surgery and diagnostic testing codes noted as covered only if selection criteria apply.

    • Covered codes include 15756, 15758, 15840-15845, 20920-20922, 61590, 64716, 64742, 64864-64868, 64885-64886, 69740-69745, 67912, 95933 (see policy CPT/HCPCS list).
    • Prior authorization is expected when selection criteria for surgical or diagnostic services are applicable per Aetna processes.
    Prior Authorization

    Prior authorization: document failed spontaneous recovery and objective findings

    For reconstructive or reanimation procedures, prior authorization should document failure of expected spontaneous recovery and provide objective electrophysiologic evidence and a proposed surgical plan.

    • Document lack of return of function after an observation period (commonly ~12 months) or objective evidence of no reinnervation (EMG/ENoG).
    • Include the proposed reconstructive procedure and planned staging (e.g., CFNG followed by FFMT).
    Prior Authorization

    Prior authorization recommended for complex reconstruction

    Prior authorization is recommended for complex reconstructive procedures and should include paralysis chronicity, prior conservative therapy, and the detailed surgical plan because these techniques are often staged and microvascular.

    • Examples include free functional muscle transfer, cross-face nerve grafting, and temporalis transfer.
    • Provide rationale for staging (e.g., CFNG then FFMT) or single-stage alternatives (e.g., masseteric nerve transfer).
    Prior Authorization

    Prior authorization: capture severity evidence and timing for decompression

    When requesting authorization for facial nerve decompression, include severity evidence and timing rationale such as complete paralysis, >90% degeneration on ENoG, absent voluntary EMG, and the timing since onset to support the surgical approach.

    • ENoG showing >90% degeneration and absent voluntary EMG (within ~14 days) are cited candidate criteria.
    • Document timing since symptom onset and rationale if decompression is being considered beyond typical early windows (references discuss ≤14 days vs up to 90 days in select cases).
    Prior Authorization

    Prior authorization: confirm prior conservative therapies before selective neurectomy/myectomy

    Prior authorization for selective neurectomy or myectomy should verify that conservative first- and second-line therapies were attempted and documented before approving surgery.

    • Document trials of chemo-denervation (Botox) and neuromuscular retraining and their outcomes.
    • Authorization decisions should reflect individualized consideration given limited long‑term evidence.
    Note

    No other prior authorization rules specified in this excerpt

    This excerpt does not specify additional prior authorization rules beyond those described elsewhere in the policy.

    • Background sections and some supplemental chunks provide evidence reviews but do not add new prior authorization requirements.
    Note

    Supplemental information: no prior authorization specified

    No prior authorization requirements are specified in the supplemental information section of the policy.

    • The Additional Information section lists external resources and does not state authorization requirements.
    Step Therapy

    No explicit step therapy sequence specified

    The policy does not define an explicit step therapy sequence for Bell's palsy treatments.

    • Treatment recommendations and evidence summaries are provided, but no mandated stepwise medication or procedure sequence is specified.
    Step Therapy

    Conservative/physical therapies preferred as initial approach

    Conservative and physical therapies (tailored facial exercises, neuromuscular retraining) are supported by low-quality evidence and are reasonable initial management prior to considering invasive procedures.

    • Physical therapy evidence is mixed; tailored facial exercises may help selected patients, particularly chronic or moderate paralysis.
    • These approaches are generally preferred initial options before surgical reconstruction when feasible.
    Note

    Document staged vs single-stage reconstruction considerations

    Document rationale when choosing staged versus single-stage reconstruction; staged approaches (e.g., CFNG then FFMT) are described as a common strategy while single-stage masseteric nerve transfers are an alternative in selected patients.

    • Staged CFNG with FFMT may restore spontaneous mimetic function; masseteric or temporalis transfers may be chosen for single-stage reconstruction or limited life expectancy.
    Documentation Required

    Document prior non-surgical therapies and outcomes before invasive procedures

    Before elective invasive procedures, document prior non-surgical therapies and their outcomes so that authorization and clinical decisions can confirm appropriate stepwise management.

    • Include facial retraining, physical therapy, PNF, and botulinum toxin treatments and the clinical response.
    • Objective functional measures and symptom duration should be recorded.
    Step Therapy

    Synkinesis: chemo-denervation and retraining first; surgery third-line

    For management of synkinesis, initial treatment typically uses chemo-denervation (Botox) and neuromuscular re-training; surgery (selective myectomy/neurectomy) is considered a later, third-line option.

    • Clinical practice recommendations designate surgery as third-line and stress individualized decision-making after discussing complications and limited success rates.
    • Document prior Botox use and retraining attempts when seeking authorization for surgical synkinesis interventions.
    Documentation Required

    Surgical coverage: document duration >12 months, functional deficit, and electrophysiology

    Documentation supporting surgical coverage must show paralysis duration greater than 12 months, an impaired functional deficit (mastication, speech, or vision), and electrophysiologic testing indicating low likelihood of spontaneous recovery.

    • Electromyography or electroneuronography findings demonstrating no reasonable likelihood of recovery are required.
    • These elements are necessary for facial surgery to be considered medically necessary.
    Documentation Required

    Surgical planning: include duration, EMG/ENoG, prior therapy, and technique rationale

    For surgical planning and authorization, include duration of paralysis, prior EMG/ENoG results, prior conservative management, and the rationale for the chosen reconstructive technique.

    • Specify timing since onset because timing and etiology influence choice and expected outcomes.
    • Describe planned staging (e.g., nerve grafting then muscle transfer) and expected goals (spontaneous mimetic function vs voluntary movement).
    Documentation Required

    Required clinical rationale: etiology, duration, prior treatments, and method justification

    Clinical rationale submitted for authorization should state etiology, duration of paralysis, prior treatments, and why the chosen reconstruction method is appropriate (e.g., direct repair, CFNG+FFMT, temporalis transfer).

    • Clarify whether the surgical goal is restoration of spontaneous mimetic function or provision of voluntary movement.
    • Relate the chosen method to patient factors such as age, comorbidity, and soft tissue deficits.
    Documentation Required

    Preoperative documentation: ENoG/EMG, imaging, HB grade, and timing rationale

    Preoperative documentation should include ENoG, EMG, imaging, and House‑Brackmann grading, with timing from symptom onset and the rationale for the selected surgical approach (e.g., middle cranial fossa vs trans‑mastoid).

    • Record electrophysiologic results (e.g., >90% degeneration on ENoG where applicable) and absent voluntary EMG when relevant to decompression candidacy.
    • Document days since onset to support timing-based decisions.
    Documentation Required

    Document prior synkinesis treatments (Botox, retraining) and outcomes

    When documenting prior synkinesis treatments for authorization, include details of prior Botox/chemo‑denervation, neuromuscular retraining, the types used, duration, and clinical response.

    • Note objective pre- and post-treatment assessments and any need for repeat injections.
    • For surgical synkinesis requests, demonstrate failure or inadequate response to first- and second-line therapies.
    Documentation Required

    Telerehabilitation: recommend detailed intervention and AE reporting

    Although no mandatory telerehabilitation documentation is specified, the policy recommends detailed reporting of telerehabilitation interventions and adverse events using standardized reporting frameworks.

    • Use TIDieR-style detail for interventions and record adverse event characteristics to support safety and outcomes reporting.
    • Maintain session documentation and AE logs even though not currently prescriptive for authorization.
    Note

    Supplemental resources: reference links for providers

    The Additional Information section provides links to Aetna resources (glossary, app, legal notices) that providers may reference but does not impose specific documentation or authorization requirements.

    • Providers may consult listed resources for administrative and general guidance; these links do not change clinical documentation expectations.
    Denial Risk

    Denial risk: experimental, investigational, or unproven procedures

    Claims for procedures listed as experimental, investigational, or unproven (such as acupuncture, antivirals, botulinum toxin, electrical stimulation, facial nerve decompression, facial retraining therapy, PRP, neuromuscular ultrasound, telerehabilitation, TMS, Vitamin B‑12) may be denied because effectiveness has not been established.

    • The policy explicitly labels numerous diagnostics and treatments as experimental/investigational/unproven and at risk for denial.
    • Review the policy's experimental/unproven list before submitting claims for these services.
    Denial Risk

    Denial risk: limited randomized evidence for surgical interventions

    Surgical interventions for Bell's palsy are supported by very low‑quality randomized evidence and trials have not demonstrated clear benefit; lack of demonstrated benefit may lead to denial when surgery is requested solely for Bell's palsy without specific indications.

    • Cochrane and systematic review data cite very low‑quality RCT evidence insufficient to conclude benefit of surgical intervention for routine Bell's palsy management.
    • Authorization should be supported by documented indications and failed conservative management where appropriate.
    Denial Risk

    Caution: limitations of procedures using non‑facial motor nerves

    Procedures that rely on motor nerves other than the facial nerve (e.g., temporalis transposition, hypoglossal or spinal accessory neurotization) have limitations and do not restore a truly spontaneous smile; these limitations should be acknowledged in planning and documentation.

    • Neurotization by the contralateral facial nerve is associated with recovery of spontaneous smile more often than transfers using non‑facial motor nerves.
    • Document expected functional outcomes and patient counseling when non‑facial nerve neurotization is proposed.
    Documentation Required

    Preoperative counseling: document discussion of hearing loss risk before decompression

    Prior to facial nerve decompression, discuss and document the risk of postoperative hearing loss (reported ~2–5%) and perform appropriate preoperative assessments; absence of documented counseling or assessments may affect coverage decisions.

    • Counsel patients on risks (including possible hearing loss) and record this discussion in the medical record.
    • Include hearing assessment data where available when seeking authorization for decompression.
    Denial Risk

    Selective myectomy/neurectomy: third‑line caution and documentation requirement

    Selective myectomy or neurectomy should be considered a third‑line, individualized option and is recommended only after failed conservative management; inadequate prior management or lack of individualized risk discussion could lead to denial.

    • Ensure prior Botox and neuromuscular retraining are documented and that the informed consent discussion addresses limited long‑term evidence and potential complications.
    • Authorization reviewers will expect demonstration of prior conservative trials.
    Note

    Background sections: no explicit authorization rules

    Several background and evidence review sections do not add explicit authorization rules; they provide context and references for clinical decision‑making but are not prescriptive for prior authorization.

    • Use these sections for clinical context; rely on the policy's prior_auth and documentation sections for authorization requirements.
    Note

    Additional information: no authorization triggers specified

    Supplemental information in the Additional Information section does not state authorization or clinical denial triggers; it lists general resources and links only.

    • Providers should not infer authorization rules from these supplemental links; follow the policy's coverage and prior authorization guidance.

    Background and Evidence Summary

    Bell's palsy is described as an acute, idiopathic peripheral facial neuropathy (cranial nerve VII) characterized by rapid-onset, unilateral facial paralysis that is usually self-limiting. Most patients recover within months (commonly by 6 months), although a minority experience delayed or incomplete recovery resulting in residual deficits such as synkinesis, impaired eyelid closure, or functional impairment of mastication, speech, or vision.

    The policy references several randomized trials and meta-analyses as key evidence sources. Notably, Sullivan et al. (a large randomized factorial trial enrolling patients within 72 hours) demonstrated a significant benefit of early prednisolone for facial recovery at 3 and 9 months. de Almeida and colleagues pooled 18 trials (n=2,786) showing corticosteroids reduce the risk of unsatisfactory recovery and that combined corticosteroid/antiviral therapy may yield additional, but inconsistent, benefit. Cochrane and other systematic reviews summarized multiple RCTs and concluded corticosteroids have the strongest evidence; antiviral benefit is uncertain and surgical evidence is very low quality.

    The policy summarizes evidence for multiple adjunctive therapies. Acupuncture meta-analyses reported higher effective response rates but were limited by study heterogeneity and bias. Antiviral trials and Cochrane reviews found no consistent additional benefit over steroids, though some subgroup or combined-treatment analyses suggested modest effects. Intra-tympanic steroid therapy (ITST) meta-analysis (3 RCTs + 2 cohorts, n≈350) suggested potential reduction in non-recovery with daily regimens but methods varied. Trials and reviews of telerehabilitation, electrotherapy, and other modalities are cited but generally graded as low-quality or needing further RCT validation.

    Electrophysiologic testing thresholds and multi-test decision models are discussed. The policy cites study-derived metrics including an ENoG degeneration index cutoff of 71.72% (orbicularis oculi), a NET difference threshold of 4.50 mA, a CMAP latency threshold of 3.80 ms in frontalis, and integrated EMG/ENoG cutoffs used in pediatric studies (e.g., 25% integrated EMG, 10% ENoG). Combined use of multiple electrophysiologic tests improved prognostic accuracy in the referenced decision-tree analysis.

    Surgical cohort evidence is summarized for reconstruction approaches. Large institutional series of gracilis free functional muscle transfer (e.g., hundreds of cases in some centers) and cohort studies of combined myectomy/neurectomy plus free muscle transfer report functional improvements; for example, a combined myectomy/neurectomy cohort (Chuang et al.) reported that 96% of patients did not require postoperative Botox, though revision rates were high. These reports are primarily Level IV cohort evidence and underscore variability in outcomes and the need for individualized surgical planning.

    Scoping reviews of telerehabilitation for facial palsy identified a growing body of literature (e.g., Yau et al. included 81 studies, 3,057 participants) and reported that adverse events related to telerehabilitation were rare (0.3% per session) and mostly mild. However, reviewers highlighted heterogeneity in study design, technologies, and reporting and recommended standardized, detailed AE reporting and use of reporting frameworks (e.g., TIDieR) to strengthen the evidence base.

    Definitions and Additional Resources

    Bell's palsy definition and core concept
    DefinitionAcute idiopathic facial paresis characterized by rapid-onset unilateral facial paralysis, often self-limiting
    Typical recovery timeframeMajority recover spontaneously within 6 months; up to 30% may have delayed or incomplete recovery
    Etiology noteMay be related to viral-triggered immune demyelination, exact cause unclear
    Blink reflex testing definition and performance characteristics
    Blink reflex testing definitionAn electrodiagnostic test assessing blink responses used in Bell's palsy evaluation
    Performance characteristicsReported diagnostic sensitivity ~81% and specificity ~94% in selected studies
    Clinical roleHelpful for lesion localization and may be under-utilized in facial nerve assessment
    Gold weight eyelid implant definition
    Gold weight eyelid implantUpper eyelid implant (e.g., gold weight) to aid closure in orbicularis oculi paresis
    Clinical benefitsReduces lagophthalmos, improves corneal coverage, resolves exposure keratitis, and can improve visual acuity
    IndicationUsed for deficient eyelid closure in complete facial nerve palsy
    Facial retraining / neuromuscular retraining definition
    Facial retraining / neuromuscular retrainingStructured therapy including exercises, EMG biofeedback, and supervised modalities to normalize movement, increase symmetry, inhibit synkinesis, and normalize tone
    Typical componentsActive self-training, EMG feedback, and supervised sessions possibly using modalities like heat/cold or massage
    EvidencePreliminary studies suggest benefit but randomized controlled trials are lacking or small
    Cross-facial nerve graft and FFMT definition
    Cross-facial nerve graft + FFMTStaged approach using contralateral facial nerve grafting (e.g., sural nerve) followed by microvascular free functional muscle transfer (commonly gracilis) to restore dynamic facial movement
    Staging noteTypical second stage performed 6–9 months after grafting to allow axonal growth
    IndicationUsed for long-standing paralysis when restoration of spontaneous mimetic function is desired
    Free functional muscle transfer (FFMT) definition
    Free functional muscle transfer (FFMT)Microvascular transplantation of a muscle (commonly gracilis) with neural reinnervation to restore dynamic facial movement
    Typical donor nervesInnervation commonly from contralateral facial nerve branches or masseteric nerve depending on approach
    UsageOften performed as staged procedure after cross-face nerve grafting; can restore spontaneous smile in selected cases
    Cross-face nerve graft (CFNG) definition
    Cross-face nerve graft (CFNG)Nerve grafting from the contralateral healthy facial nerve to the paralyzed side to provide axonal donor input for reinnervation
    PurposeProvides donor axons to reinnervate transferred muscle allowing potential spontaneous smile recovery
    Typical techniqueOften uses sural nerve grafts in a staged reconstruction algorithm
    Masseteric nerve transfer definition
    Masseteric nerve transferUse of the motor branch to the masseter as a donor nerve to reinnervate a muscle transfer (e.g., gracilis) allowing earlier voluntary contraction and single-stage reconstruction
    Clinical outcomeCan lead to voluntary smile contraction early; some patients later develop spontaneous smile without jaw movement
    IndicationConsidered for single-stage reconstructions or when rapid reinnervation is preferred
    House-Brackmann (HB) scale definition
    House-Brackmann (HB) scaleClinical grading system for facial nerve function used to assess severity and recovery
    Use in studiesCommon outcome measure in decompression and reconstruction literature
    GradesRanges typically from I (normal) to VI (complete paralysis)
    Electroneurography (ENoG) definition
    Electroneurography (ENoG)Electrophysiologic test assessing facial nerve degeneration used to quantify percent degeneration and guide prognosis
    Clinical thresholds>90% degeneration cited as indicator for decompression consideration; specific DI values used in prognostic models
    TimingENoG commonly performed in early weeks after onset to inform prognosis
    Synkinesis definition
    SynkinesisAberrant, involuntary muscle activity from misdirected nerve regeneration causing uncoordinated contractions (e.g., eyelid narrowing with smile)
    Clinical impactCan produce functional impairment and cosmetic concerns such as asymmetric smile and tension
    ManagementFirst-line: botulinum toxin and neuromuscular re-training; surgery considered when refractory
    Free functional platysma transfer definition
    Free functional platysma transferMicrosurgical transfer of vascularized platysma muscle to restore dynamic eye closure and blink in longstanding facial paralysis
    OutcomesReported restoration of blink reflex and improved full eye closure in pediatric series; Level IV evidence
    IndicationConsidered for patients with permanent orbicularis oculi denervation when less invasive options are unsuitable
    Surface EMG (sEMG) definition
    Surface EMG (sEMG)Noninvasive recording of facial muscle electrical activity using skin-surface electrodes to assess symmetry and function
    Potential roleObjective quantification tool for facial function; methods heterogeneous and evidence limited
    Recommended useAdjunctive assessment, for serial monitoring or research rather than sole basis for major surgical decisions
    ENoG / integrated EMG definition and usage
    ENoG / integrated EMGCombination of electroneurography (degeneration index) and integrated needle EMG used to quantify degeneration and improve prognostic accuracy
    Decision-model evidenceHeo et al decision-tree combined ENoG DI, CMAP latency, NET, and HB grade achieving ~86% accuracy
    Pediatric dataCombined integrated EMG ≤25% with ENoG <10% improved specificity and accuracy in predicting incomplete recovery in children
    Telerehabilitation (TR) definition
    Telerehabilitation (TR)Remote delivery of rehabilitation services via asynchronous, synchronous, or hybrid modes (video, phone, text, apps, internet systems)
    Safety findingsScoping review: 295 adverse events during 84,534 sessions (0.3%); most AEs physical, mild/non-severe, and often unrelated to TR
    RecommendationDetailed reporting of interventions and adverse events recommended for future studies
    Adverse events (AEs) in telerehabilitation — definition and examples
    Adverse events (AEs) in telerehabilitationEvents such as falls during physiotherapy or aspiration pneumonia during speech therapy; in one scoping review AEs occurred at 0.3% per session
    Severity and relatednessMajority were physical, mild/non-serious, and often unrelated to telerehabilitation
    Reporting recommendationUse TIDieR guidelines for detailed AE reporting in future studies
    Glossary / Additional resources links
    Glossary & resourcesLinks to Aetna glossary, mobile app, FAQs, legal notices, program provisions and other resources
    PurposeSupplemental materials providers and members may reference for administrative and educational content
    Access noteLinks provided in Additional Information section of policy
    Language assistance — availability and referenced languages
    Language assistance availabilityLanguage services can be provided by calling the number on the member ID card
    Referenced languagesIncludes Español, 中文, Tiếng Việt, 한국어, Tagalog, Pусский, العربية, Kreyòl, Français, Polski, Português, Italiano, Deutsch, 日本語, فارسی, and others
    Where listedAdditional Information section of the policy contains links and language listing

    Revision History

    2008-02-08policy_effective

    Policy effective date recorded.

    2025-10-30last_reviewLatest

    Policy underwent most recent review (documented as last review).

    2026-08-27next_review_scheduled

    Next scheduled policy review date recorded.